SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
SPRC stock price ended at $0.68 on 火曜日, after rising 0.00%
On the latest trading day Feb 10, 2026, the stock price of SPRC rose by 0.00%, climbing from $0.66 to $0.68. During the session, the stock saw a volatility of 7.81%, with prices oscillating between a daily low of $0.64 and a high of $0.69. Notably, trading volume dropped by -- shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 94.7K shares were traded, equating to a market value of approximately $2.2M.